ASCO 2015 Highlights

Long-term outcomes from MAIA support the use of daratumumab plus lenalidomide and dexamethasone for ≥18 months in newly diagnosed, transplant ineligible MM patients.

Final analysis of ICARIA-MM demonstrated a 6.9-month improvement in survival with Isa-Pd compared to Pd alone in RRMM patients.

Meta-analysis of whole-body MRI versus FDG PET/CT to assess treatment response in MM may suggest a complementary benefit when utilizing both modalities.

Updated phase 2 results of the MonumenTAL-1 study showed promising efficacy and a tolerable safety profile with talquetamab, a novel T-cell–redirecting bispecific antibody, in patients with RRMM.

Real-world analysis of patients with MM determines treatment patterns and survival outcomes in patients with t(11;14) compared to patients with high- and standard-risk cytogenetics.

REGN5458, a BCMAxCD38 bispecific antibody, demonstrated early durable responses with a tolerable safety profile and low rates of CRS in patients with relapsed/refractory multiple myeloma.

Phase 2 results from MajesTEC-1 showed substantial clinical activity with teclistamab and are consistent with phase 1 findings.

Phase 1 data of ALLO-715 followed by lymphodepletion showed durable responses in heavily pretreated RRMM patients.

Results from cohort A of MagnetisMM-3 showed promising efficacy and a tolerable safety profile with elranatamab in RRMM patients naïve to BCMA-targeted treatment.

Results of patient-reported outcomes from the GRIFFIN study showed improved health-related quality of life in patients with NDMM with the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone.